Publikationen (Auswahl, seit 2004)

C. Spurny, S. Kailayangiri, S. Jamitzky, B. Altvater, W. Hartmann, E. Wardelmann, U. Dirksen, J. Hardes, C. Rossig. Programmed cell death ligand-1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. Ped Blood Cancer 2017, in press M. Trautmann, J. Menzel, C. Bertling, M. Cyra, I. Isfort, K. Steinestel, I. Grünewald, B. Altvater, C. Rossig, S. Fröhling, S. Hafner, T. Simmet, P. Åman, E. Wardelmann, S. Huss, W. Hartmann. The FUS-DDIT3 fusion protein drives IGF-IR/PI3K/Akt signaling in myxoid liposarcoma. Clin Cancer Res 2017 Jun 21. pii: clincanres.0130.2017 C. Rossig, M. Pule, B. Altvater, S. Saiagh, G. Wright, S. Ghorashian, L. Clifton-Hadley, K. Champion, Z. Sattar, B. Popova, A. Hackshaw, P. Smith, T. Roberts, E. Biagi, B. Dreno, R. Rousseau, S. Kailayangiri, M. Ahlman, R. Hough, B. Kremens, M. Sauer, P. Veys, N. Goulden, M. Cummins, P. Amrolia. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017; 31:1087-1095 J. Albring, S. Inselmann, T. Sauer, C. Schliemann, B. Altvater, S. Kailayangiri, C. Rossig, W. Hartmann, J. R. Knorrenschild, K. Sohlbach, C. Groth, M. Lohoff, A. Neubauer, W. Berdel, A. Burchert, M. Stelljes. PD-1 checkpoint blockade in patients with relapsed acute myeloid leukaemia (AML) after allogeneic stem cell transplantation (SCT). Bone Marrow Transplant. 2017 Feb;52(2):317-320 S. Kailayangiri, B. Altvater, C. Spurny, S. Jamitzky, S. Schelhaas, A. H. Jacobs, C. Wiek, K. Roellecke, H. Hanenberg, W. Hartmann, H. Wiendl, J. Meltzer, N. Farwick, L. Greune, C. Rossig. Targeting Ewing sarcoma with activated and GD2-specific chimeric receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology. 2016 Oct 28;6(1):e1250050 M. Tanaka, H. Tashiro, J. Ando, N. Lapteva, B. Omer, M. Ngo, G. Dotti, P. R. Kinchington, A. Leen, C. Rossig, C. M. Rooney. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells. Clin Cancer Res. 2017 Feb 9. pii: clincanres.2138.2016 K. Roellecke, E. Virts, R. Einholz, K. Edson, B. Altvater, C. Rossig, D. Von Laer, K. Scheckenbach, M. Wagenmann, D. Reinhardt, C. Kramm, A. Rettie, C. Wiek, H. Hanenberg. Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. Gene Ther. 2016 Jul;23(7):615-26 Bäumer N, Appel N, Terheyden L, Buchholz F, Rossig C, Müller-Tidow C, Berdel WE, Bäumer S.Protection and guidance of antibody-coupled siRNA leads to a novel efficient method for in vivo mRNA knockdown. Nature Protocols 11(1):22-36,2016 Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, Korsching E, Buch T, Weckesser M, Schulze I, Besoke R, Witten A, Stoll M, Köhler G, Hartmann W, Wardelmann E, Rossig C, Baumhoer D, Jürgens H, Burdach S, Berdel WE, Müller-Tidow C. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma. Clin Cancer Res. 2015 Nov 1;21(21):4935-46 J. P. H. Fisher, B. Flutter, F. Wesemann, J. Frosch, C. Rossig, K. Gustafsson, J. Anderson. Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with V9V2+ T cells. OncoImmunology 2015 Apr 27;5(1):e1025194 S. Jamitzky, A. C Krueger, S. Janneschuetz, S. Piepke, S. Kailayangir, C. Spurny, C. Rossig, B. Altvater. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells. Pediatr Blood Cancer. 2015 Nov;62(11):1979-85 C. Schliemann, K. L. Gutbrodt, M. Pohlen, A. Kerkhoff, S. Wiebe, L Angenendt, T. Kessler, R. M. Mesters, L. Giovannoni, B. Altvater, C. Rossig, G. Köhler, D. Neri, M. Stelljes, W. E. Berdel. Targeting Interleukin-2 to the Bone Marrow Vasculature for Therapy of Acute Myeloid Leukemia Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Immunol Res 3(5):547-56;2015 B. Altvater, S. Kailayangiri, N. Theimann, C. Chen, S. Pscherer, I. Neumann, G. Mrachatz, A. Hansmeier, J. Hardes, U. Dirksen, H. Juergens, C. Rossig. Ewing sarcoma-associated antigens fail to induce efficient T cell responses in both patients and healthy individuals. Cancer Immunol Immunother 63:1047-60, 2014 K. Leuchte, S. Kailayangiri, B. Altvater, S. Hoffschlag, J. Meltzer, S. Pscherer, A. Luecke, J. Potratz, M. Ahlmann, U. Dirksen, C. Rossig. Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. Oncology Reports 32:845-852, 2014 L. Liebsch, S. Kailayangiri, L. Beck, B. Altvater, R. Koch, C. Dierkes, M. Hotfilder, N. Nagelmann, J. Ring, C. Faber, V. Vieth, C. Rossig. Ewing sarcoma dissemination and therapeutic response to experimental T cell therapy in mice assessed by whole body magnetic resonance imaging. V.V. and C.R. share senior authorship. Br J Cancer 109:658-66, 2013 I. Lustfeld, B. Altvater, M. Ahlmann, S. Ligges, P. Brinkrolf, C. Katerkamp, A. Rosemann, A. Moericke, C. Rossig. High proportions of CD4+ T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses. Acta Haematol 131:28-36, 2013 S.-K. Mueller, B. Altvater, C. Chen, S. Kailayangiri, M. Ahlmann, U. Dirksen, H. Juergens, C. Rossig. Zoledronic acid negatively affects expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells. Oncol Rep 29:2348-54, 2013 S. Kailayangiri, B. Altvater, J. Meltzer, S. Pscherer, A. Luecke, U. Titze, C. Dierkes, K. Leuchte, S. Landmeier, M. Hotfilder, U. Dirksen, J. Hardes, G. Gosheger, H. Juergens, C. Rossig. The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106:1123-33, 2012 B. Altvater, S. Pscherer, S. Landmeier, S. Kailayangiri, H. Juergens, C. Rossig. Activated human  T cells induce peptide-specific CD8+ T cell responses to tumor-associated self antigens. Cancer Immunol Immunother 61:385-96, 2012 C. I.-U. Chen*, S. Koschmieder*, L. Kerstiens, M. Schemionek, B. Altvater, S. Pscherer, H. T. Maecker, W. E. Berdel, H. Juergens, P. P. Lee, C. Rossig. NK cells are dysfunctional in human chronic myelogenous leukemia and in BCR-ABL-positive mice. * share first authorship. Leukemia 26:465-74, 2012 C. U. Louis, B. Savoldo, G. Dotti, M. Pule, E. Yvon, G. D. Myers, C. Rossig, H. V. Russell, O. Diouf, E. Liu, H. Liu, M.-F. Wu, A. Gee, Z. Mei, C. M. Rooney, H. E. Heslop, M. K. Brenner. Anti-tumor activity and long-term fate of chimeric antigen receptor positive T-cells in patients with neuroblastoma. Blood 118:6050-6, 2011 S. Landmeier, B. Altvater, S. Pscherer, J. Meltzer, N. Sebire, M. Pule, J. Vera, M. Hotfilder, H. Juergens, J. Vormoor, C. Rossig. Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo (Letter). Leukemia 24:1080-4, 2010 B. Altvater, S. Landmeier, S. Pscherer, J. Temme, K. Schweer, S. Kailayangiri, D. Campana, H. Juergens, M. Pule, C. Rossig. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 15, 4857-66, 2009 (Editorial Clin Cancer Res 15:4790-1, 2009) P. Brinkrolf, S. Landmeier, B. Altvater, C. Chen, S. Pscherer, A. Rosemann, A. Ranft, U. Dirksen, H. Juergens, C. Rossig. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 125:879-86, 2009 B. Altvater, S. Landmeier, S. Pscherer, J. Temme, H. Juergens, M. Pule, C. Rossig. 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. Cancer Immunol Immunother 85:1991-2001, 2009 S. Landmeier, B. Altvater, S. Pscherer, H. Juergens, L. Varnholt, A. Hansmeier, C. M. Bollard, A. Moosmann, G. Bisping, C. Rossig. Activated human  T cells as stimulators of specific CD8+ T cell responses to subdominant Epstein Barr virus (EBV) epitopes: Potential for immunotherapy of cancer. J Immunother 32:310-321, 2009 M. A. Pule, B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti, M. H. Huls, E. Liu, A. P. Gee, Z. Mei, E. Yvon, H. L. Weiss, C. M. Rooney, H. E. Heslop, M. K. Brenner. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in neuroblastoma patients. Nature Medicine 14:1264-70, 2008 S. Landmeier, B. Altvater, S. Pscherer, B. R. Eing, J. Kuehn, C. M. Rooney, H. Juergens, C. Rossig. Gene-engineered Varicella-Zoster-Virus-reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res 67:8335-43, 2007 J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. Heslop, C. Rooney, M. K. Brenner, G. Dotti. T-lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B-lymphocyte derived malignant cells. Blood 108:3890-3897, 2006 Loskog, V. Giandomenico, C. Rossig, M. Pule, G. Dotti, M.K. Brenner. Addition of the CD28 signaling domain to chimeric T cell receptors enhances chimeric T cell resistance to T regulatory cells. Leukemia 20:1819-1828, 2006 Altvater, S. Pscherer, S. Landmeier, V. Niggemeier, H. Juergens, J. Vormoor, C. Rossig. CD28 fails to costimulate tumor-specific activation of virus-specific memory effector T cells. Clin Exp Immunol, 144:447-457, 2006 S. Gattenloehner, A. Marx, B. Markfort, S. Pscherer, S. Landmeier, H. Juergens, H.-K. Mueller-Hermelink, I. Matthews, D. Beeson, A. Vincent, C. Rossig. Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. Cancer Res, 66:24-28, 2006 C. Rossig, A. Baer, S. Pscherer, B. Altvater, M. Pule, C. M. Rooney, M. K. Brenner, H. Juergens, J. Vormoor. Target antigen expression on a professional antigen-presenting cell induces superior proliferative anti-tumor T cell responses via chimeric T cell receptors. J Immunother 29:21-31, 2006 M. Pieper, C. Scheffold, S. Duwe, C. Rossig, G. Bisping, M. Stelljes, T. F. Tedder, H. Jurgens, W. E. Berdel, J. Kienast. Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. Leukemia 20:729-32, 2006 C. Rossig, S. Pscherer, S. Landmeier, B. Altvater, H. Jürgens, J. Vormoor. Adoptive cellular immunotherapy with CD19-specific T cells. Klin Päd 217:351-356, 2005 M. Rischer, S. Pscherer, S. Duwe, J. Vormoor, H. Jürgens, C. Rossig. Human gd T cells as mediators of chimeric-receptor redirected antitumor immunity. Br J Haematol 126:583-529, 2004

Prof. Dr. med. Claudia Rössig Hier finden Sie eine Übersicht der Mitglieder der Arbeitsgruppe.
Hier finden Sie eine Auswahl der Publikationen seit 2004.